These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 28109631)

  • 1. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
    Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
    Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy.
    Lin AJ; Samson P; Zoberi J; Garcia-Ramirez J; Williamson JF; Markovina S; Schwarz J; Grigsby PW
    Brachytherapy; 2019; 18(3):353-360. PubMed ID: 30971370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].
    Du XX; Yang H; Zhang HJ; Li LA; Fan WS; Meng YG
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):679-686. PubMed ID: 29060966
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix.
    Forrest JL; Ackerman I; Barbera L; Barnes EA; Davidson M; Kiss A; Thomas G
    Int J Gynecol Cancer; 2010 Aug; 20(6):1074-8. PubMed ID: 20683420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes with image-based interstitial brachytherapy for vaginal cancer.
    Manuel MM; Cho LP; Catalano PJ; Damato AL; Miyamoto DT; Tempany CM; Schmidt EJ; Viswanathan AN
    Radiother Oncol; 2016 Sep; 120(3):486-492. PubMed ID: 27321150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical outcomes of ultrasound-guided CT-planned high-dose-rate interstitial brachytherapy for primary locally advanced cervical cancer.
    Mesko S; Swamy U; Park SJ; Borja L; Wang J; Demanes DJ; Kamrava M
    Brachytherapy; 2015; 14(5):626-32. PubMed ID: 26024784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose-Rate Brachytherapy Boosting Concurrent Chemoradiation as a Definitive Treatment Modality for Cervical Cancer: Long-term Clinical Results of Outcomes and Associated Toxicity.
    Refaat T; Donnelly ED; Gentile M; Novak C; Yuan Y; Khedr GA; Helenowksi I; Lurain J; Schink J; Rademaker A; Sathiaseelan V; Strauss JB; Small W
    Am J Clin Oncol; 2016 Apr; 39(2):196-203. PubMed ID: 24487420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computed Tomography-Planned High-Dose-Rate Brachytherapy for Treating Uterine Cervical Cancer.
    Zolciak-Siwinska A; Gruszczynska E; Bijok M; Jonska-Gmyrek J; Dabkowski M; Staniaszek J; Michalski W; Kowalczyk A; Milanowska K
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):87-92. PubMed ID: 27375169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
    Mayer A; Nemeskéri C; Petneházi C; Borgulya G; Varga S; Naszály A
    Strahlenther Onkol; 2004 Apr; 180(4):209-15. PubMed ID: 15057431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.
    Kim DH; Wang-Chesebro A; Weinberg V; Pouliot J; Chen LM; Speight J; Littell R; Hsu IC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1329-34. PubMed ID: 19409728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience.
    Cho LP; Manuel M; Catalano P; Lee L; Damato AL; Cormack RA; Buzurovic I; Bhagwat M; O'Farrell D; Devlin PM; Viswanathan AN
    Gynecol Oncol; 2016 Dec; 143(3):545-551. PubMed ID: 27720445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported sexual adjustment after definitive chemoradiation and MR-guided brachytherapy for cervical cancer.
    Conway JL; Gerber R; Han K; Jiang H; Xie J; Beiki-Ardakani A; Fyles A; Milosevic M; Williamson D; Croke J
    Brachytherapy; 2019; 18(2):133-140. PubMed ID: 30509730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.
    Romano KD; Pugh KJ; Trifiletti DM; Libby B; Showalter TN
    Brachytherapy; 2017; 16(2):378-386. PubMed ID: 28139420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes.
    Tinkle CL; Weinberg V; Chen LM; Littell R; Cunha JAM; Sethi RA; Chan JK; Hsu IC
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1093-1100. PubMed ID: 26194683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.